Direkt zum Inhalt
Merck
Alle Fotos(1)

Wichtige Dokumente

Gesamtdokumentation anzeigen

D-915

Supelco

Desalkylflurazepam -Lösung

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise
Alle Fotos(1)

About This Item

Empirische Formel (Hill-System):
C15H10ClFN2O
CAS-Nummer:
2886-65-9
Molekulargewicht:
288.70
EG-Nummer:
200-659-6
MDL-Nummer:
MFCD00083443
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Qualitätsniveau

300

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland)

Konzentration

1.0 mg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

clinical testing

Format

single component solution

Lagertemp.

−20°C

SMILES String

Fc1ccccc1C2=NCC(=O)Nc3ccc(Cl)cc23

InChI

1S/C15H10ClFN2O/c16-9-5-6-13-11(7-9)15(18-8-14(20)19-13)10-3-1-2-4-12(10)17/h1-7H,8H2,(H,19,20)

InChIKey

UVCOILFBWYKHHB-UHFFFAOYSA-N

Allgemeine Beschreibung

Desalkylflurazepam, also known as N-desalkyl-2-oxoquazepam, is a long-acting metabolite of the benzodiazepine drug flurazepam. Flurazepam is sold unde the trade names Dalmane and Dalmadorm for the treatment of mild to moderate insomnia. This Certified Spiking Solution® is suited for use in LC/MS or GC/MS applications for clinical toxicology, forensic analysis or urine drug testing.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

D-924

Desalkylflurazepam-d4 -Lösung, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-003

Flurazepam -Lösung, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-901

2-Hydroxyethylflurazepam solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-902

2-Hydroxyethylflurazepam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-919

2-Hydroxyethylflurazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

H-923

2-Hydroxyethylflurazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes,Central nervous system

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 2

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup

Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

J Hilbert et al.
Drug metabolism and disposition: the biological fate of chemicals, 12(4), 452-459 (1984-07-01)
The disposition of 14C-quazepam (7-chloro-(2,2,2-trifluoroethyl) [5-14C]-5-o-fluorophenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-thione), a new benzodiazepine hypnotic, was studied in hamsters and mice after iv and po dosing. In both species, quazepam was rapidly absorbed, as indicated by the plasma Cmax being reached within 1 hr of
Y Sakai et al.
Japanese journal of pharmacology, 37(4), 373-379 (1985-04-01)
A new benzodiazepine compound, ethyl loflazepate (ethyl-7-chloro-2,3-dihydro-5-(2-fluorophenyl)-2-oxo-1H,1,4- benzodiazepine-3-carboxylate; CM6912) was studied using in vitro experimental systems for its displacement activity on 3H-diazepam binding to the synaptosomal membrane fraction of rat cerebrum and potentiating action on GABA. CM6912 inhibited the specific
S K Gupta et al.
Pharmaceutical research, 5(6), 365-368 (1988-06-01)
A reverse-phase liquid chromatographic method is described for simultaneous quantification of quazepam, and two of its metabolites, 2-oxoquazepam and N-desaklyl-2-oxoquazepam. The method uses a solid-phase extraction procedure to prepare plasma samples. After extraction, the methanolic extract is evaporated; the residue
J M Hilbert et al.
Clinical pharmacology and therapeutics, 36(4), 566-569 (1984-10-01)
The kinetics of quazepam, a benzodiazepine hypnotic, was studied in 10 geriatric subjects. Each received one 15-mg tablet of quazepam. Blood samples were collected before and at specified times (up to 672 hr) after dosing. Plasma concentrations of quazepam and
K Schaffler et al.
Arzneimittel-Forschung, 39(2), 276-283 (1989-02-01)
To assess pharmacodynamic and pharmacokinetic properties of acute, subchronic and withdrawn quazepam, a single-blind, longitudinal study was run in eight male, healthy young volunteers. The design covered a 1-week placebo run-in period, a period with daily oral night-time administration of
Alle zugehörigen Dokumente anzeigen

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.